Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study.
Valenza C, Nicolò E, Mongillo M, Trapani D, Katrini J, Boldrini L, Boscolo Bielo L, Castellano G, Guidi L, Pellizzari G, Villa J, Derio S, Lapresa M, Gigli F, Parma G, Omodeo Salè E, Derenzini E, Curigliano G, Colombo N.
Valenza C, et al. Among authors: guidi l.
Oncologist. 2024 Nov 28:oyae330. doi: 10.1093/oncolo/oyae330. Online ahead of print.
Oncologist. 2024.
PMID: 39607864
Free article.